In one paragraphArticle in Biosensors, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
11 authors.
Bartomeu MestreMultidisciplinary Sepsis Group, Health Research Institute of the Balearic Islands (IdISBa), 07120 Palma de Mallorca, Spain.ORCID 0009-0006-1352-8412 Nuria Toledo-PonsInflamación, Reparación y Cáncer en Enfermedades Respiratorias (I-RESPIRE) Group, Health Research Institute of the Balearic Islands (IdISBa), 07120 Palma de Mallorca, Spain.ORCID 0000-0002-2599-4473 Andreu VaquerMultidisciplinary Sepsis Group, Health Research Institute of the Balearic Islands (IdISBa), 07120 Palma de Mallorca, Spain.ORCID 0000-0002-7983-5881 Sofia TejadaMultidisciplinary Sepsis Group, Health Research Institute of the Balearic Islands (IdISBa), 07120 Palma de Mallorca, Spain.ORCID 0000-0002-2000-6587 Antonio ClementeGroup of Innovation in Immunopathology of Infections (GTERi), Health Research Institute of the Balearic Islands (IdISBa), 07120 Palma de Mallorca, Spain.ORCID 0000-0002-0412-1315 Amanda IglesiasInflamación, Reparación y Cáncer en Enfermedades Respiratorias (I-RESPIRE) Group, Health Research Institute of the Balearic Islands (IdISBa), 07120 Palma de Mallorca, Spain.ORCID 0000-0003-2525-7796 Meritxell LópezInflamación, Reparación y Cáncer en Enfermedades Respiratorias (I-RESPIRE) Group, Health Research Institute of the Balearic Islands (IdISBa), 07120 Palma de Mallorca, Spain.ORCID 0000-0002-1805-1987 Ruth EngongaInflamación, Reparación y Cáncer en Enfermedades Respiratorias (I-RESPIRE) Group, Health Research Institute of the Balearic Islands (IdISBa), 07120 Palma de Mallorca, Spain.ORCID 0009-0009-1829-2762 Sabina PerellóInflamación, Reparación y Cáncer en Enfermedades Respiratorias (I-RESPIRE) Group, Health Research Institute of the Balearic Islands (IdISBa), 07120 Palma de Mallorca, Spain.ORCID 0009-0006-1196-0025 Borja G CosíoInflamación, Reparación y Cáncer en Enfermedades Respiratorias (I-RESPIRE) Group, Health Research Institute of the Balearic Islands (IdISBa), 07120 Palma de Mallorca, Spain.ORCID 0000-0002-6388-8209 Roberto de la RicaMultidisciplinary Sepsis Group, Health Research Institute of the Balearic Islands (IdISBa), 07120 Palma de Mallorca, Spain.ORCID 0000-0002-5750-1469 Funding
"Impuesto del Turismo Sostenible" of the Balearic Islands government Expedient ITS2023-057 "CONSCIENCIA IdISBa: Consolidar la ciencia IdISBa" program FOLIUM JR23/02Instituto de Salud Carlos III (ISCIII) Miguel Servet contract, CP23/00151Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union Project PI23/01692MICIU/AEI/10.13039/501100011033 and by "European Union NextGenerationEU/PRTR" Grant CNS2022-135324the Instituto de Salud Carlos III (ISCIII) PFIS contract FI21/00167
6 · The paper itselfAbstract
Patients with chronic obstructive pulmonary disease (COPD) often experience acute exacerbations characterized by elevated neutrophilic inflammation in the lungs. Currently, this condition is diagnosed through visual inspection of sputum color and volume, a method prone to personal bias and unsuitable for patients who are unable to expectorate spontaneously. In this manuscript, we present a novel approach for measuring and monitoring exhaled myeloperoxidase (MPO), a biomarker of neutrophilic airway inflammation, without the need for sputum analysis. The method involves analyzing an unmodified surgical facemask worn by the patient for 30 min using biosensing decals that transfer antibody-coated nanoparticles. These colloids specifically interact with MPO trapped by the facemask in a dose-dependent manner, enabling the quantification of MPO levels, with a dynamic range up to 3 · 10
Indexed as
Biosensing TechniquesMasksNanoparticlesPulmonary Disease, Chronic ObstructiveBiomarkersFemaleHumansImmunoassayInflammationMaleMiddle AgedNeutrophilsPeroxidaseBiomarkersPeroxidasebiosensorbreathchronic obstructive pulmonary diseaseexacerbationmyeloperoxidase
Identifiers
PMID40422062
PMCPMC12110278
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390